Compare Sony Group Corp (SONY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sony Group Corp vs Zimmer Biomet Holdings Inc — how do they compare? Sony Group Corp trades at $23.44 (market cap $138.43B), while Zimmer Biomet Holdings Inc trades at $95.95 (market cap $18.55B). The key difference: Sony Group Corp is far larger — about 7.5× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (0.99%). Which is the better fit depends on your goals.
| SONY | ZBH | |
|---|---|---|
Market Cap | $138.43B | $18.55B |
Sector | Technology | Health |
52-Week High | $30.26 | $107.71 |
52-Week Low | $19.32 | $79.58 |
Enterprise Value | $136.35B | $25.61B |
Dividend Yield | 0.67% | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sony (SONY) trades at $23.82, up 1.53% over the past day, with a bullish technical signal from moving averages and oscillators. Recent earnings show mixed quarterly results, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. The company reported strong operating cash flow of $2.32 trillion in 2025, though net income margin turned negative at -1.75% for 2026. Positive sentiment is driven by blockbuster Spider-Man performance and a joint venture with TSMC for image sensors.
The outlook is cautiously optimistic, supported by analyst consensus with 68.75% buy ratings and a 29.75% upside potential. Key opportunities include growth in gaming and sensors, while risks involve profitability pressures and competitive threats. Investors should weigh strong cash flow against margin volatility.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
